New Partnership Opens New Opportunities

Joint-related diseases have notably become more prevalent among younger individuals, approximately 15 years earlier than in the past, due to various factors including fast-paced lifestyles, environmental issues, and excessive fitness activities, among other significant yet smaller factors. Consequently, the demand for safe and effective treatments is currently very high.

At the recent Health Ingredients Europe exhibition in Frankfurt am Main, Germany, representatives from Ideal Pharma Peptide reached an agreement with Biova USA for the joint development of a next-generation chondroprotector. This new product is based on the arthropeptide complex IPH AEN/DES, which features a high concentration of Desmosine.

The arthropeptide complex IPH AEN/DES represents a cutting-edge and conceptually novel product designed for the prevention of musculoskeletal disorders such as arthritis, osteoarthritis, osteochondrosis, and rheumatism. Further details on this development will be provided in subsequent updates.